With cancer foot forward, Step making strides toward clinic with €35M series B

As Step contemplated two paths forward into autoimmune and cancer indications for its lead program, the French biotech concluded that the oncology route offered a shorter route to a potential accelerated approval.

Now, Step Pharma S.A.S. has drawn €35 million ($41.7 million) in series B funding from a syndicate led by Hadean Ventures and Sunstone Life Science Ventures designed to fund the company through a proof-of-concept study in T cell malignancies...